Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme: Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 4, 2008, Pages 186-187

  Schiff, David ^a   Purow, Benjamin ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CORTICOSTEROID; CYTOTOXIC AGENT; FLUORINE 18; IRINOTECAN; NITROSOUREA; TEMOZOLOMIDE; THYMIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; GLIOBLASTOMA; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; SHORT SURVEY;

EID: 41849092968     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1077     Document Type: Short Survey

References (5)

1. Vredenburgh JJ et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 1253-1259
2. Batchelor TT et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95
3. Pope WB et al. (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: 1258-1260
4. 18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25: 4714-4721
5. Rubenstein JL et al. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314